| 17575237 |
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647
Jackman, L,
Ventura, R,
Shi, Y,
De Costa, A,
Zhang, W,
Keast, P,
Engell, K,
Wang, J,
Chen, J,
Yu, P,
Lutman, J,
Bentzien, F,
Laird, AD,
Joly, AH,
Meyer, SM,
Martini, JF,
Yakes, FM,
Gendreau, SB,
Jaeger, CT,
Cancilla, B,
Chu, F,
Aftab, DT
|
Clin. Cancer Res. |
2007 |
| 12214266 |
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Spector, NL,
Alligood, KJ,
Rusnak, DW,
Liu, LH,
Keith, BR,
Owens, G,
Ma, H,
Mullin, RJ,
Xia, W
|
Oncogene |
2002 |
| 15093539 |
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Sliwkowski, MX,
Leahy, DJ,
Vajdos, FF,
de Vos, AM,
Carey, KD,
Franklin, MC
|
Cancer Cell |
2004 |
| 20145185 |
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer
Ogilvie, D,
Smith, P,
Speake, G,
Anderton, J,
Beck, S,
Wilkinson, RW,
Vincent, J,
Barlaam, B,
Hickinson, DM,
Klinowska, T,
Marshall, G,
Davenport, S,
Callis, R,
Trigwell, C,
Grosios, K,
Mills, E
|
Clin. Cancer Res. |
2010 |
| 2566907 |
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
Fendly, BM,
Shepard, HM,
Winget, M,
Hudziak, RM,
Lewis, GD,
Ullrich, A
|
Mol. Cell. Biol. |
1989 |
| 18408761 |
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Meyerson, M,
Li, D,
Wong, KK,
Ambrogio, L,
Chirieac, LR,
Takahashi, M,
Shimamura, T,
Shapiro, GI,
Baum, A,
Rettig, WJ,
Padera, RF,
Himmelsbach, F,
Solca, F,
Kubo, S,
Greulich, H
|
Oncogene |
2008 |
| 11278435 |
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition
Nelson, JM,
Fry, DW
|
J. Biol. Chem. |
2001 |
| 15374980 |
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
Rusnak, DW,
Wood, ER,
Lackey, K,
Yuan, D,
Horne, E,
Pennisi, C,
Gilmer, TM,
Dickerson, SH,
Shewchuk, L,
Alligood, KJ,
Truesdale, AT,
Hassell, A,
Ellis, B,
McDonald, OB
|
Cancer Res. |
2004 |
| 15256466 |
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity
Allegrini, PR,
McSheehy, P,
Mestan, J,
Traxler, P,
Fabbro, D,
Caravatti, G,
Brandt, R,
Wartmann, M,
Wood, J,
Brueggen, J,
Tang, C,
Meyer, T,
Lane, HA,
Cozens, R,
Grosios, K
|
Cancer Res. |
2004 |
| 18978815 |
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
Pickl, M,
Ries, CH
|
Oncogene |
2009 |
| 1350088 |
Humanization of an anti-p185HER2 antibody for human cancer therapy
Shepard, HM,
Henner, D,
Carver, ME,
Rowland, AM,
Ridgway, JB,
Kotts, C,
Wong, WL,
Carter, P,
Gorman, CM,
Presta, L
|
Proc. Natl. Acad. Sci. U.S.A. |
1992 |
| 29490608 |
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Nami, B,
Wang, Z,
Maadi, H,
Li, G,
Tong, J
|
BMC Cancer |
2018 |
| 17942920 |
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor
Finn, RS,
Emerson, EO,
Campbell, M,
Steyn, SJ,
Pustilnik, LR,
Morris, J,
Bhattacharya, SK,
Kath, JC,
Connell, RD,
Rossi, AM,
Floyd, E,
Moyer, JD,
Coleman, KG,
Harriman, S,
Wagner, L,
Jani, JP,
Ralston, S,
Winter, SM,
Currier, N,
Rafidi, K
|
Cancer Res. |
2007 |
| 28274957 |
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
Hyman, DM,
Solit, DB,
Nagy, R,
Sheehan, JH,
Sliwoski, GR,
Berger, MF,
He, J,
Lalani, AS,
Brewer, MR,
Miller, V,
Cross, D,
Cutler, RE,
Hanker, AB,
Lanman, R,
Arteaga, CL,
Koch, JP,
Lovly, CM,
Meiler, J
|
Cancer Discov |
2017 |
| 15173008 |
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
Johnson, BD,
Overbeek, E,
Baxter, M,
Wissner, A,
Shen, R,
Wang, YF,
Tsou, HR,
Floyd, MB,
Discafani, CM,
Rabindran, SK,
Nilakantan, R,
Rosfjord, EC,
Golas, J,
Reich, MF,
Shi, X,
Hallett, WA
|
Cancer Res |
2004 |
